Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

In addition, AstraZeneca recently announced its fourth and fifth Phase ... coupled with lower COMP503 expenses mainly related ...

The Guildford, England-based liquid biopsy company said the study undertaken by the National & Kapodistrian University of Athens used the Parsortix system to isolate and harvest circulating tumour ...

Inc. , a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB (Alliance)/SWOG 80702 randomized, phase III clinical trial. CALGB ...

DMD Systems Recovery, LLC (DMD), a Reuse Firsttm IT Asset Disposition (ITAD) services provider, proudly announces its recognition as a Gartner® Representative Provider in the 2024 Gartner Market Guide ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter and first nine months of 2024. Net sales rose 5% to $502 million in Q3 2024 over Q3 2023, while ...

Through base editing, drugs replace single nucleotide in the DNA strand with another ... in Europe in 2020 and in the US last year, and AstraZeneca recently reported phase 2b data with a monthly ...